Tadalafil Tablet, Film Coated
Product Images NDC 68071-3936

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3936). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3936 3)

Label for Tadalafil 5 mg tablets, film-coated, oral dosage form by NuCare Pharmaceuticals, Inc. The label indicates a package size of 30 tablets, Rx only. It includes product number R1858030, manufacturer info from Hetero Labs Limited, India, and patient instructions area. Storage instructions specify controlled temperature 68-77°F and a warning to keep out of reach of children.*

FDA Label Image

Camber1jpj (Camber1jpg)

FDA Label Image

Tadalafilfigure1.jpg (Tadalafilfigure1)

This image contains four line graphs illustrating the difference in blood pressure measurements over time in hours. The graphs display changes in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure comparing Tadalafil to placebo, with time points from 0 to 96 hours on the x-axis and blood pressure difference in mmHg on the y-axis.*

FDA Label Image

Tadalafilfigure2.jpg (Tadalafilfigure2)

A two-part line graph showing the effect of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo plus doxazosin 8 mg on systolic blood pressure (BP) over 24 hours. The upper graph depicts standing systolic BP changes, the lower graph shows supine systolic BP changes, both measured in mmHg against time post-dose in hours.*

FDA Label Image

Tadalafilfigure4.jpg (Tadalafilfigure4)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo. The x-axis shows time after administration, and the y-axis shows systolic blood pressure changes. The graph compares 20 mg tadalafil given at 08:00 and 20:00 with placebo, each combined with 8 mg doxazosin daily at 08:00, showing multiple overlapping trend lines.*

FDA Label Image

Tadalafilfigure5.jpg (Tadalafilfigure5)

A pharmacokinetic chart showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens of tadalafil. The plot includes data points and trends for a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg tadalafil following five consecutive days of administration, illustrating concentration changes up to 120 hours.*

FDA Label Image

Tadalfilfigure6.jpg (Tadalafilfigure6)

A line graph depicting the change from baseline in IPSS (International Prostate Symptom Score) total score over a 12-week treatment duration comparing Tadalafil 5 mg and placebo. The graph shows greater improvement with Tadalafil 5 mg, with statistically significant difference (p<0.01) indicated.*

FDA Label Image

Tadalafilfigure7.jpg (Tadalafilfigure7)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil 5 mg and placebo. The graph shows a greater decrease in IPSS score with Tadalafil 5 mg than placebo, with statistically significant differences marked at certain points.*

FDA Label Image

Tadalafilfigure8 (Tadalafilfigure8)

A line graph showing least squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph includes data points at 4, 12, and 26 weeks, indicating statistically significant differences between the two groups, with Tadalafil/Finasteride showing greater improvement.*

FDA Label Image

Tadalfilfigure9.jpg (Tadalafilfigure9)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment. It compares Tadalafil and placebo groups, plotting duration of treatment in weeks on the x-axis and change in score on the y-axis, with Tadalafil showing a greater decrease compared to placebo. Statistically significant differences are indicated.*

FDA Label Image

Tadalafilstructure.jpg (Tadalafilstructure)

Chemical structure of the active ingredient tadalafil. The diagram shows the molecular arrangement of atoms characteristic of tadalafil, a prescription drug used orally in tablet form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.